Kidney Fibrosis Treatment Market Size, Share, Trends, Growth and Forecast 2032

Kidney Fibrosis Treatment Market Insights

According to a report from Zion Market Research, the global Kidney Fibrosis Treatment Market was valued at USD 4.78 Billion in 2023 and is projected to hit USD 7.65 Billion by 2032, with a compound annual growth rate (CAGR) of 4.8% during the forecast period 2024-2032.

This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Kidney Fibrosis Treatment Market industry over the next decade.

Request Free Sample

Introduction

Kidney fibrosis is caused as a result of excess gathering of extracellular matrix and symbolizes a failure of wound healing procedure of tissues of kidney. In addition to this, kidney fibrosis is a method that results in end-stage renal disorder. Rising cases of chronic kidney disorders and kidney fibrosis along with rise in the patient population base has resulted in the need for kidney fibrosis treatment in the recent years. In addition to this, renal fibrosis results in particular damage or disorder of kidney. Diabetes, heart problems, and family history of chronic kidney disorder are few of the causes of kidney fibrosis.

Kidney Fibrosis Treatment Market, By Therapeutic

• Angiotensin Converting Enzyme Inhibitors
• Vasopeptidase Inhibitors
• Pirfenidone
• Angiotensin Ii Receptor Blockers
• Renin Inhibitors

Based on Therapeutic, the market is segmented into Angiotensin Converting Enzyme Inhibitors, Vasopeptidase Inhibitors, Pirfenidone, Angiotensin Ii Receptor Blockers, and Renin Inhibitors. The segment of angiotensin converting enzyme inhibitors is expected to hold the largest market share as they are used to work in reducing the production of angiotensin II, a powerful stimulator of renal fibrosis. Renal fibrosis is characterized by the formation of scar tissue in lieu of kidney tissue. Although ACE inhibitors have been used to treat heart failure and hypertension, they are most commonly used to treat chronic kidney disease (CKD).

Kidney Fibrosis Treatment Market, By End-User

• Clinics
• Research Center
• Hospitals

Based on End-User, the market is segmented into Clinics, Research Center, and Hospitals. The segment of the research center is anticipated to hold the largest market share owing to the increase in R&D facilities for the creation of innovative renal disease medications. Additionally, during the projected period, the incidence rates of CKD are expected to grow across all age groups, and government spending for kidney disease-related R&D will increase along with it.

Request Free Sample

Kidney Fibrosis Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Kidney Fibrosis Treatment Market: Report Scope

Market Growth Drivers

Escalating occurrence of chronic disorders due to unhealthy food habits has resulted in kidney fibrosis cases, thereby culminating into huge market demand in the upcoming years. Surge in the aging population along with massive awareness pertaining to renal fibrosis therapy will prompt the kidney fibrosis market expansion over the forthcoming years. Rise in the frequency of obesity with changing food patterns has resulted in increase in kidney problems, thereby driving the market earnings.

Moreover, rise in health consciousness among the various age-groups of population will culminate into massive market penetration across the globe over the upcoming years. Nonetheless, strict laws pertaining to approval of kidney fibrosis therapy may put brakes on the industry growth over the forecast timeframe.

North America To Erupt As Global Market Leader During Forecast Timeframe

The expansion of kidney fibrosis treatment market in North America over the estimated timeframe is attributed to surge in the population base suffering from kidney ailments. In addition to this, rise in the launching of end-stage kidney disorder therapy in the country such as the U.S. will provide lucrative growth avenues for kidney fibrosis treatment market in North America over the assessment period. Rise in the CRO activities and surge in the healthcare spending in the U.S. and Canada has further added to the expansion of the market in the region. As per CDC, nearly 37 million adult populations were slated to have been affected due to chronic kidney ailments during 2019. This accounted for 15% of total adult population in the U.S.  Apart from this, CDC has reported that in the U.S. children above the age of 18 suffer from polycystic kidney disorder and glomerulonephritis. All these aforementioned factors will drive the demand for kidney fibrosis therapy in the U.S., thereby driving the regional market trends.

Key participants profiled in the report are -

• InterMune Inc.
• Merck & Co.
• Pfizer Inc.
• La Jolla Pharmaceutical Company
• F. Hoffman-La Roche Ltd.
• Galectin Therapeutics
• BioLine Rx Ltd.
• Genzyme Corporation
• ProMetic Life-Sciences Inc

The global kidney fibrosis treatment market is segmented as follows:

By therapeutics:

• Angiotensin II receptor blockers (ARBs)
• Angiotensin Converting Enzyme (ACE) inhibitors
• Pirfenidone
• Renin Inhibitors
• Vasopeptidase Inhibitors

By location of testing:

• Public health hospitals
• Hospital testing
• Commercial/private hospitals
• Clinics
• Home Treatment

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa